Nuveen Asset Management’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $6.45M | Buy |
1,903,442
+228,380
| +14% | +$774K | ﹤0.01% | 1858 |
|
|
2024
Q3 | $4.77M | Buy |
1,675,062
+332,450
| +25% | +$947K | ﹤0.01% | 2012 |
|
|
2024
Q2 | $3.02M | Sell |
1,342,612
-247,890
| -16% | -$558K | ﹤0.01% | 2183 |
|
|
2024
Q1 | $3.52M | Buy |
1,590,502
+1,165,530
| +274% | +$2.58M | ﹤0.01% | 2141 |
|
|
2023
Q4 | $999K | Sell |
424,972
-287,725
| -40% | -$676K | ﹤0.01% | 2734 |
|
|
2023
Q3 | $1.33M | Buy |
712,697
+293,130
| +70% | +$545K | ﹤0.01% | 2459 |
|
|
2023
Q2 | $1.1M | Sell |
419,567
-1,849
| -0.4% | -$4.84K | ﹤0.01% | 2604 |
|
|
2023
Q1 | $687K | Sell |
421,416
-5,405
| -1% | -$8.81K | ﹤0.01% | 2725 |
|
|
2022
Q4 | $567K | Sell |
426,821
-23,362
| -5% | -$31K | ﹤0.01% | 2855 |
|
|
2022
Q3 | $702K | Buy |
450,183
+5,259
| +1% | +$8.2K | ﹤0.01% | 2872 |
|
|
2022
Q2 | $685K | Buy |
+444,924
| New | +$685K | ﹤0.01% | 2936 |
|
|
2021
Q2 | – | Sell |
-135,618
| Closed | -$612K | – | 3448 |
|
|
2021
Q1 | $612K | Sell |
135,618
-12,794
| -9% | -$57.7K | ﹤0.01% | 3052 |
|
|
2020
Q4 | $730K | Sell |
148,412
-374
| -0.3% | -$1.84K | ﹤0.01% | 2915 |
|
|
2020
Q3 | $883K | Sell |
148,786
-12,916
| -8% | -$76.7K | ﹤0.01% | 2734 |
|
|
2020
Q2 | $430K | Sell |
161,702
-14,592
| -8% | -$38.8K | ﹤0.01% | 2959 |
|
|
2020
Q1 | $344K | Buy |
176,294
+53,664
| +44% | +$105K | ﹤0.01% | 2893 |
|
|
2019
Q4 | $865K | Sell |
122,630
-1,117
| -0.9% | -$7.88K | ﹤0.01% | 2736 |
|
|
2019
Q3 | $1.22M | Buy |
123,747
+50,940
| +70% | +$501K | ﹤0.01% | 2615 |
|
|
2019
Q2 | $833K | Buy |
+72,807
| New | +$833K | ﹤0.01% | 2804 |
|